Alzheimer's disease and inflammatory biomarkers positively correlate in plasma in the UK‐ADRC cohort

Abstract

AbstractINTRODUCTIONProtein‐based plasma assays provide hope for improving accessibility and specificity of molecular diagnostics to diagnose dementia.METHODSPlasma was obtained from participants (N = 837) in our community‐based University of Kentucky Alzheimer's Disease Research Center cohort. We evaluated six Alzheimer's disease (AD)‐ and neurodegeneration‐related (Aβ40, Aβ42, Aβ42/40, p‐tau181, total tau, and NfLight) and five inflammatory biomarkers (TNF𝛼, IL6, IL8, IL10, and GFAP) using the SIMOA‐based protein assay platform. Statistics were performed to assess correlations.RESULTSOur large cohort reflects previous plasma biomarker findings. Relationships between biomarkers to understand AD–inflammatory biomarker correlations showed significant associations between AD and inflammatory biomarkers suggesting peripheral inflammatory interactions with increasing AD pathology. Biomarker associations parsed out by clinical diagnosis (normal, MCI, and dementia) reveal changes in strength of the correlations across the cognitive continuum.DISCUSSIONUnique AD–inflammatory biomarker correlations in a community‐based cohort reveal a new avenue for utilizing plasma‐based biomarkers in the assessment of AD and related dementias.Highlights Large community cohorts studying sex, age, and APOE genotype effects on biomarkers are few. It is unknown how biomarker–biomarker associations vary through aging and dementia. Six AD (Aβ40, Aβ42, Aβ42/40, p‐tau181, total tau, and NfLight) and five inflammatory biomarkers (TNFα, IL6, IL8, IL10, and GFAP) were used to examine associations between biomarkers. Plasma biomarkers suggesting increasing cerebral AD pathology corresponded to increases in peripheral inflammatory markers, both pro‐inflammatory and anti‐inflammatory. Strength of correlations, between pairs of classic AD and inflammatory plasma biomarker, changes throughout cognitive progression to dementia.